According to a research report published earlier today, Ladenburg Thalmann has lowered AMAG Pharmaceuticals' AMAG PT from $19.50 to $19.
Ladenburg Thalmann said in the report, “We continue to believe AMAG's valuation continues to be partially sustained by investor expectations for a potential acquisition or other commercial strategic move(s). To this end, we believe the Street (and us) assigns a high probability of success to the ongoing label expansion initiative to include general iron deficiency anemia (IDA). We expect data from the first Feraheme Phase 3 trial in general IDA later this week.”
Ladenburg Thalmann maintains its Buy rating on AMAG Pharmaceuticals, which closed yesterday at $16.09.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in